Compare Quest Diagnostics Inc (DGX) vs MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs MicroSectors FANG and Innovation 3X Leveraged ETN — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.82 (market cap $2.98B). The key difference: Quest Diagnostics Inc is far larger — about 8.6× MicroSectors FANG and Innovation 3X Leveraged ETN's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days on average.
| DGX | FNGU | |
|---|---|---|
Market Cap | $25.48B | $2.98B |
Volume | 941,866 | 4,682,352 |
Sector | Health | Leveraged / Inverse |
52-Week High | $247.45 | $37.20 |
52-Week Low | $173.49 | $13.73 |
Typical Hold Time | 56 Days | 19 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
FNGU, a 3x leveraged ETN tracking major tech stocks, trades at $36.82, down 1.02% today. Technical signals are bullish based on moving averages, with neutral oscillators suggesting potential consolidation. Support and resistance levels are tightly clustered between $33 and $39, indicating a critical price zone. Recent news highlights the ETN's high volatility, having lost 87% during past tech sector downturns, underscoring its leveraged risk profile.
The outlook for FNGU hinges on sustained strength in its underlying tech holdings like Nvidia and Apple. While bullish momentum offers upside potential, the extreme leverage amplifies risks during market corrections. Investors face significant volatility, with losses magnified in downturns, making it suitable only for those with high risk tolerance and short-term horizons.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →
